Skip to main content

Advertisement

Table 6 Univariate analysis for risk factors for early death (within 90 days after treatment initiation)

From: Fluoropyrimidine with or without platinum as first-line chemotherapy in patients with advanced gastric cancer and severe peritoneal metastasis: a multicenter retrospective study

Variable Univariate analysis
N OR [95% CI] p-value
Age (years)
 < 65 11/61 1.00   
 ≥65 17/68 1.52 [0.65–3.56] 0.34
Sex
 Male 17/68 1.00   
 Female 11/61 0.66 [0.28–1.55] 0.34
ECOG PS
 0–1 13/77 1.00   
 2–4 15/52 2.00 [0.86–4.65] 0.11
Disease status
 Advanced 28/120 NC   NC
 Recurrent 0/9
Primary site
 Stomach 26/123 1.00   
 GEJ (vs. stomach) 2/6 1.87 [0.32–10.76] 0.49
No. of metastatic sites
 1–2 19/100 1.00   
 ≥3 9/29 1.92 [0.76–4.87] 0.17
Subtype of SPM
 Massive ascites 16/62 1.00   
 Inadequate oral intake 7/35 0.72 [0.26–1.96] 0.52
 Both 5/32 0.53 [0.18–1.62] 0.27
Serum albumin level
> 3.1 g/ml 10/68 1.00   
 < 3.1 g/ml 18/61 2.43 [1.02–5.78] 0.05
Serum CRP level
 < 2.2 mg/dl 8/62 1.00   
> 2.2 mg/dl 20/67 2.87 [1.16–7.13] 0.02
  1. CI confidence interval, CRP C-reactive protein, ECOG PS Eastern Cooperative Oncology Group performance status, GEJ gastroesophageal junction, NC not calculated, OR odds ratio, SPM severe peritoneal metastasis